Colleen Labelle MSN

Published on 11/1/2021

Komaromy M, Tomanovich M, Taylor JL, Ruiz-Mercado G, Kimmel SD, Bagley SM, Saia KM, Costello E, Park TW, LaBelle C, Weinstein Z, Walley AY. Adaptation of a System of Treatment for Substance Use Disorders During the COVID-19 Pandemic. J Addict Med. 2021 Nov-Dec 01; 15(6):448-451. PMID: 33298750.

Published on 9/1/2021

Wason K, Potter A, Alves J, Loukas VL, Lastimoso C, Sodder S, Caputo A, LaBelle CT. Addiction Nursing Competencies: A Comprehensive Toolkit for the Addictions Nurse. J Nurs Adm. 2021 Sep 01; 51(9):424-429. PMID: 34411061.

Published on 7/28/2021

Tsui JI, Leroux BG, Radick AC, Schramm ZA, Blalock K, Labelle C, Heerema M, Klein JW, Merrill JO, Saxon AJ, Samet JH, Kim TW. Video directly observed therapy for patients receiving office-based buprenorphine - A pilot randomized controlled trial. Drug Alcohol Depend. 2021 10 01; 227:108917. PMID: 34399136.

Published on 1/31/2021

Campbell CI, Saxon AJ, Boudreau DM, Wartko PD, Bobb JF, Lee AK, Matthews AG, McCormack J, Liu DS, Addis M, Altschuler A, Samet JH, LaBelle CT, Arnsten J, Caldeiro RM, Borst DT, Stotts AL, Braciszewski JM, Szapocznik J, Bart G, Schwartz RP, McNeely J, Liebschutz JM, Tsui JI, Merrill JO, Glass JE, Lapham GT, Murphy SM, Weinstein ZM, Yarborough BJH, Bradley KA. PRimary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. Addict Sci Clin Pract. 2021 01 31; 16(1):9. PMID: 33517894.

Published on 9/25/2018

Bagley SM, Cheng DM, Winter M, Alford DP, LaBelle C, Walley AY, Samet JH. Opioid and cocaine use among primary care patients on buprenorphine-Self-report and urine drug tests. Drug Alcohol Depend. 2018 11 01; 192:245-249. PMID: 30290291.

Published on 6/19/2018

Weinstein ZM, Gryczynski G, Cheng DM, Quinn E, Hui D, Kim HW, Labelle C, Samet JH. Tapering off and returning to buprenorphine maintenance in a primary care Office Based Addiction Treatment (OBAT) program. Drug Alcohol Depend. 2018 08 01; 189:166-171. PMID: 29958128.

Published on 5/16/2017

Hui D, Weinstein ZM, Cheng DM, Quinn E, Kim H, Labelle C, Samet JH. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine. J Subst Abuse Treat. 2017 Aug; 79:12-19. PMID: 28673522.

Published on 12/30/2016

Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, Drainoni ML, Bachman SS, Samet JH. Long-term retention in Office Based Opioid Treatment with buprenorphine. J Subst Abuse Treat. 2017 Mar; 74:65-70. PMID: 28132702.

Published on 6/26/2015

LaBelle CT, Han SC, Bergeron A, Samet JH. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers. J Subst Abuse Treat. 2016 Jan; 60:6-13. PMID: 26233698.

Published on 1/1/2015

Tierney M, Finnell DS, Naegle MA, LaBelle C, Gordon AJ. Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers. Subst Abus. 2015; 36(4):389-92. PMID: 26587696.